Here are relevant reports on : parkinsons-disease-market
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) & Region - Global Forecast to 2027
The global enteral feeding formulas market growth is primed to transition from $5.2 billion in 2022 to $8.2 billion by 2027, showcasing a strong CAGR of 9.5%. Factors such as rising healthcare expenditure; a surge in the number of preterm births worldwide; growing aging population in need for enteral feeding; rising prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases, and neurological disorders; growing awareness of enteral nutrition benefits; and rapid improvements in healthcare facilities in emerging countries are expected to further drive the market during the forecast period.
- Published: August 2022
- Price: $ 4950
- TOC Available:
-
Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028
The global molecular quality controls market, valued at US$0.2 billion in 2022, stood at US$0.2 billion in 2023 and is projected to advance at a resilient CAGR of 6.6% from 2023 to 2028, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The growth of this market is primarily driven by the increasing number of accredited clinical laboratories, growing adoption of third-party quality controls, and increasing government funding for genomic projects.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
Europe Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Europe biomarkers Market, valued at US$16.40 billion in 2024, stood at US$17.46 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$28.11 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
- Published: October 2017
- Price: $ 4950
- TOC Available:
-
Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Test Strips Market by Product Type (Blood test strip, Urine Test Strip), Application (Diabetes, Infectious Disease, Cardiac Marker Testing), End-use (Hospitals, Home Care, Diagnostic Laboratories) - Global Forecast to 2027
The global test strips market is projected to reach USD 12.9 billion by 2027 from USD 11.4 billion in 2021, at a CAGR of 2.1% during the forecast period . The growth of test strips market is owing to Increasing prevalence of diabetes across the globe, rising preference for point of care testing, and increasing technological advancements in test strips whereas the low accuracy of test strips are restraining this market up to certain extent.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028
The global cardiac marker testing market, valued at US$4.1 billion in 2022, stood at US$4.4 billion in 2023 and is projected to advance at a resilient CAGR of 9.4% from 2023 to 2028, culminating in a forecasted valuation of US$6.9 billion by the end of the period. Increase in chronic heart conditions and aging population, increasing research & funding initiatives from organizations and worldwide rise in prevalence of cardiovascular diseases are a few drivers that collectively contribute to the growth of this market.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Bioabsorbable Stents Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022
The global bioresorbable stents market is projected to reach USD 417.2 Million by 2022, at a CAGR of 11.5%. Market growth of bioresorbable stents is attributed to the growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and patients’ preference for minimally invasive therapies. However, factors such as the increasing product withdrawals due to severe complications of these stents may hamper market growth. The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
- Published: August 2017
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
